Back to articles

News Press release : Balt receives IDE approval from the FDA to begin the STEM Trial All news

May, 14th 2020

Balt announced today it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin The Squid Trial for the Embolization of the Middle meningeal artery (STEM) for the treatment of chronic Sub-Dural Hematoma.

Discover the press release

Last modification: 2 June 2020